RTU Formulation
Enhancing Safety and Preventing Preparation Errors

GC Green Cross is expanding its product lineup by introducing an infusion bag formulation of its influenza treatment, Peramiflu.


Product image of GC Green Cross's 'Peramiflu Flu Premix Injection'. GC Green Cross

Product image of GC Green Cross's 'Peramiflu Flu Premix Injection'. GC Green Cross

View original image

GC Green Cross announced on July 1 that it has received approval from the Ministry of Food and Drug Safety for a label change for 'Peramiflu Flu Premix Injection' and will begin supplying it to medical institutions starting in July.


Peramiflu Flu Premix Injection is an injectable treatment used for both type A and type B influenza virus infections, based on peramivir, a neuraminidase inhibitor currently available in Korea.


This product has been developed as an RTU (Ready-to-Use) infusion bag formulation that can be administered without a separate dilution process. Compared to the existing vial formulation, it reduces the preparation steps for healthcare professionals, increasing convenience and minimizing the possibility of errors during preparation.


Peramiflu is an influenza treatment administered as a single intravenous injection, and it has been used for pediatric and elderly patients who have difficulty taking oral medications, as well as for patients requiring rapid treatment.



A GC Green Cross representative stated, "With the launch of Peramiflu Flu Premix Injection, we have expanded our portfolio of peramivir-based products," adding, "We will continue to strive to provide a safe and convenient treatment environment with products that reflect the needs of the medical field." GC Green Cross plans to supply Peramiflu Flu Premix Injection to medical institutions starting in July, in line with the influenza season.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing